Cycuria is developing engineered cytokine-based therapies that specifically target leukemic cells and their progenitor stem cells, aiming to improve treatment outcomes for patients with hematological cancers and difficult-to-treat solid tumors. This approach addresses the limitations of traditional therapies, which often fail to provide durable remissions and long-term survival for patients, particularly those who cannot tolerate intensive treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many hematological cancers, such as Acute Myeloid Leukemia (AML), have poor long-term outcomes despite advancements in treatment. Current therapies often fail to provide durable remissions, especially for older patients or those unable to tolerate intensive chemotherapy or stem cell transplants. This results in a significant unmet need for more targeted and less toxic therapeutic options.
Solution
Cycuria is developing engineered cytokine-based therapies designed to selectively target leukemic cells, including their progenitor stem cells, while preserving healthy blood formation. This approach aims to overcome the limitations of traditional cancer treatments by directly targeting cancer cells and minimizing systemic toxicity. By leveraging protein engineering and cytokine biology, Cycuria's therapies offer a novel strategy to improve treatment outcomes and provide hope for patients with hematological cancers and difficult-to-treat solid tumors. The company's approach focuses on achieving durable remissions and improving long-term survival rates, particularly for patients who cannot tolerate intensive treatments.
Target Audience
The primary target audience includes patients with hematological cancers, particularly those with Acute Myeloid Leukemia (AML) and other difficult-to-treat solid tumors, as well as the clinicians who treat them.
Features
- Engineered cytokines designed for specific targeting of leukemic cells and progenitor stem cells.
- Preservation of healthy blood formation to minimize treatment-related complications.
- Minimized systemic toxicity compared to traditional chemotherapy regimens.
- Utilizes protein engineering to optimize cytokine activity and specificity.